Nomacopan · rVA576, REV-576

What is Nomacopan?

Nomacopan (Coversin) is a recombinant peptide derived from a tick saliva protein that binds a unique site on complement protein C5, blocking its cleavage into C5a and C5b and preventing membrane-attack complex assembly. It also binds and inhibits leukotriene B4. It is studied in paroxysmal nocturnal hemoglobinuria and thrombotic microangiopathies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

rVA576, REV-576, REV-675, Coversin

Drug type

Recombinant protein

Targets

Complement C5 (C5), Leukotriene B4 (secondary target)

Mechanism

Inhibitor of Complement C5 (C5)

Pathways

Terminal complement pathway, Membrane-attack complex (C5b-9) assembly, Leukotriene B4 inflammatory signaling

Therapy area

Hematology

Developer

AKARI Therapeutics (AKTX)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 3

UNII

79V7Q9VIWQ

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)Thrombotic Microangiopathies

Other drugs acting on C5

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT03427060
• ClinicalTrials.gov NCT03829449
• ClinicalTrials.gov NCT04784455

Updated Oct 11, 2026. Something wrong or missing? Report it on the AKTX page.